# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Processa Pharmaceuticals shares jumped 37.5% after hours following a strong regular session, despite facing significant losses ...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers th...
Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0...